Elsmarieke van de Giessen
Overview
Explore the profile of Elsmarieke van de Giessen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
1169
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dijkstra J, Vermunt L, Venkatraghavan V, Ozhegov G, Coomans E, Ossenkoppele R, et al.
Alzheimers Res Ther
. 2025 Mar;
17(1):57.
PMID: 40051009
Background: Rare variants of the triggering receptor expressed on myeloid cell 2 (TREM2) gene are strong risk factors for Alzheimer's disease (AD), and drugs targeting the TREM2 protein are being...
2.
Scheijbeler E, de Haan W, Coomans E, den Braber A, Tomassen J, Ten Kate M, et al.
Brain Commun
. 2025 Feb;
7(1):fcaf018.
PMID: 40008329
With the ongoing developments in the field of anti-amyloid therapy for Alzheimer's disease, it is crucial to better understand the longitudinal associations between amyloid-β deposition and altered network activity in...
3.
van den Berg R, Butterbrod E, de Boer C, Schluter L, Van Harten A, Teunissen C, et al.
Alzheimers Dement (Amst)
. 2025 Jan;
17(1):e70063.
PMID: 39822289
Introduction: We examined semantic and phonemic fluency in individuals with subjective cognitive decline (SCD) in relation to amyloid status and clinical progression. Methods: A total of 490 individuals with SCD...
4.
Vermeiren M, Calandri I, van der Flier W, van de Giessen E, Ossenkoppele R
Alzheimers Dement (Amst)
. 2024 Nov;
16(4):e70033.
PMID: 39583643
Background: Recent advancements in Alzheimer's disease (AD) biomarker research and clinical trials prompt reflection on the value and consequently appropriate use of tau positron emission tomography (tau-PET) in the future....
5.
Vermeiren M, Somsen J, Luurtsema G, Reesink F, Verwey N, Hempenius L, et al.
Alzheimers Res Ther
. 2024 Oct;
16(1):230.
PMID: 39427210
Background: Tau-PET is a diagnostic tool with high sensitivity and specificity for discriminating Alzheimer's disease (AD) dementia from other neurodegenerative disorders in well-controlled research environments. The role of tau-PET in...
6.
Bader I, Groot C, Tan H, Milongo J, den Haan J, Verberk I, et al.
Alzheimers Res Ther
. 2024 Aug;
16(1):190.
PMID: 39169442
Background: Alzheimer's disease (AD) is a common, complex and multifactorial disease that may require screening across multiple routes of referral to enable early detection and subsequent future implementation of tailored...
7.
Mathies F, Heeman F, Visser P, den Braber A, Yaqub M, Klutmann S, et al.
Clin Nucl Med
. 2024 Aug;
49(9):838-846.
PMID: 39102811
Purpose: Visual interpretation of brain amyloid-β (Aβ) PET can be difficult in individuals with borderline Aβ burden. Coregistration with individual MRI is recommended in these cases, which, however, is not...
8.
van den Berg R, de Boer C, Zwan M, Jutten R, van Liere M, van de Glind M, et al.
Alzheimers Res Ther
. 2024 Aug;
16(1):176.
PMID: 39090738
Background: Digital speech assessment has potential relevance in the earliest, preclinical stages of Alzheimer's disease (AD). We evaluated the feasibility, test-retest reliability, and association with AD-related amyloid-beta (Aβ) pathology of...
9.
Hendriksen H, de Rijke T, Fruijtier A, van de Giessen E, Van Harten A, van Leeuwenstijn-Koopman M, et al.
Alzheimers Dement
. 2024 Aug;
20(9):6556-6565.
PMID: 39087383
Introduction: We disclosed amyloid positron emission tomography (PET) results in individuals with subjective cognitive decline (SCD) and studied patient experiences and outcomes over a 6-month period. Methods: Fifty-seven participants from...
10.
Koster M, van der Pluijm M, van de Giessen E, Schrantee A, van Hooijdonk C, Selten J, et al.
Schizophr Res
. 2024 Jul;
271:144-152.
PMID: 39029144
Tobacco smoking is highly prevalent among patients with psychosis and associated with worse clinical outcomes. Neurometabolites, such as glutamate and choline, are both implicated in psychosis and tobacco smoking. However,...